Global Cytokine Release Syndrome Treatment Market Forecast: Key Growth Drivers, Trends, From 2025 To 2034

The Business Research Company's Cytokine Release Syndrome Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, February 14, 2025 /EINPresswire.com/ -- The cytokine release syndrome treatment market has been witnessing a rapid growth in recent years. The market size, which was at $1.25 billion in 2024, is expected to grow to $1.42 billion in 2025 at a compound annual growth rate CAGR of 13.7%. This growth during the historic period can be attributed to the increasing prevalence of cancer, the rising adoption of immunotherapy, an upsurge in biopharmaceutical investments, an increase in clinical trials, and the growth in personalized medicine.

What Lies Ahead for the Cytokine Release Syndrome Treatment Market?

In the next few years, the cytokine release syndrome treatment market size is poised to experience rapid growth. Forecasts predict the market will expand to $2.35 billion in 2029 at a compound annual growth rate CAGR of 13.4%. This growth in the forecast period can be attributed to an increase in the prevalence of autoimmune disorders, higher incidence of cancer therapies, a wider availability of targeted therapies, increased investment in biotechnology and life sciences, and a rising use of monoclonal antibodies. Major trends in the forecast period include the implementation of biomarker-based therapies, the development of next-generation IL-6 inhibitors, advancements in CAR-T cell therapy, the adoption of biosimilars, and advancements in monoclonal antibody therapies.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp

How the Increased Prevalence of Cancer Treatments is Driving the Market Forward

The increasing prevalence of cancer treatments is expected to significantly propel the growth of the cytokine release syndrome CRS treatment market. The growing prevalence of cancer treatments is largely driven by the rising global incidence of cancer and advancements in diagnostic technologies. This allows for earlier detection and a broader range of treatment options. Additionally, improved survival rates and expanded access to healthcare contribute to the growing demand for these therapies. CRS treatment involves supportive care, anti-cytokine therapies, and ongoing monitoring to manage symptoms and mitigate the inflammatory response caused by cancer treatments. In line with this, the National Health Service NHS, a UK-based healthcare system, reported in January 2023 that over 320,000 people received cancer treatment from November 2021 to October 2022. This figure is the highest number ever recorded and represents an increase of over 8,000 compared to previous periods. This increase in the prevalence of cancer treatments is driving the cytokine release syndrome treatment market forward.

Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/cytokine-release-syndrome-treatment-global-market-report

Which Companies are Shaping the Future of the Cytokine Release Syndrome Treatment Market?

Key industry players in the cytokine release syndrome treatment market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB publ, Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, and bluebird bio Inc.

What are the Key Trends Influencing the Cytokine Release Syndrome Treatment Market?

The emergence of advanced drug delivery technologies, such as intravenous infusion, is a trend to watch in the cytokine release syndrome treatment market. Intravenous infusion in CRS treatment allows for fast and accurate administration of drugs, ensuring prompt therapeutic action and enhancing patient outcomes. To illustrate, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received regulatory approval for Actemra tocilizumab, an additional indication for treating CRS caused by cancer therapy.

How is the Cytokine Release Syndrome Treatment Market Categorized?

The cytokine release syndrome treatment market can be categorized by:

1 Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2 Administration: Intravenous, Subcutaneous, Oral
3 Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4 End User: Hospitals, Specialty Clinics, Home Care Settings

Subcategories include corticosteroids such as Prednisone, Dexamethasone, Methylprednisolone; Monoclonal Antibodies such as Tocilizumab IL-6 Inhibitor, Siltuximab IL-6 Inhibitor, Anakinra IL-1 Receptor Antagonist; and Other Immunosuppressants such as Janus Kinase JAK Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor TNF Inhibitors.

Where are the Regional Hotspots in the Cytokine Release Syndrome Treatment Market?

In 2024, North America held the largest share of the cytokine release syndrome treatment market. The report covers regions encompassing Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa, providing comprehensive regional insights.

Browse for more similar reports-
Invasive Fungal Infections Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Acute Bacterial Skin And Skin Structure Infections Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report
Hospital Acquired Infections Testing Kits Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Stay ahead in the game with The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company offers comprehensive, data-rich research and insights. With 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, you can get all the information you need.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
X
LinkedIn